FTC wins decision blocking Edwards Lifesciences' proposed JenaValve acquisition

True

Evidence from credible sources supports the statement as accurate. Learn more in Methodology.

Interesting: 0/0 • Support: 0/0Log in to vote

enforcement

The proposed acquisition of JenaValve by Edwards Lifesciences was halted (blocked) by the FTC/court action.

Source summary
The Federal Trade Commission says it secured a legal victory that halted Edwards Lifesciences Corp.'s proposed acquisition of JenaValve Technology, Inc. The action, which followed a six-day trial concluding January 9, 2026, is described by the FTC as aimed at lowering healthcare costs and expanding access to lifesaving medical devices. The agency posted a press release with further details.
Latest fact check

On January 9, 2026 the U.S. District Court for the District of Columbia granted the FTC’s request for a preliminary injunction preventing Edwards Lifesciences from acquiring JenaValve, according to an FTC press release. Edwards announced it will not acquire JenaValve following the court order, and reporting from Reuters and industry outlets confirmed the court blocked the deal. Verdict: True — primary (FTC) and company statements and independent news reporting show the FTC halted the proposed acquisition and Edwards abandoned the transaction.

Timeline

  1. Update · Jan 13, 2026, 12:35 AMTrue
    On January 9, 2026 the U.S. District Court for the District of Columbia granted the FTC’s request for a preliminary injunction preventing Edwards Lifesciences from acquiring JenaValve, according to an FTC press release. Edwards announced it will not acquire JenaValve following the court order, and reporting from Reuters and industry outlets confirmed the court blocked the deal. Verdict: True — primary (FTC) and company statements and independent news reporting show the FTC halted the proposed acquisition and Edwards abandoned the transaction.
  2. Original article · Jan 12, 2026

Comments

Only logged-in users can comment.
Loading…